These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 15972957)

  • 1. Aberrant beta-catenin signaling in tuberous sclerosis.
    Mak BC; Kenerson HL; Aicher LD; Barnes EA; Yeung RS
    Am J Pathol; 2005 Jul; 167(1):107-16. PubMed ID: 15972957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tuberin-hamartin complex negatively regulates beta-catenin signaling activity.
    Mak BC; Takemaru K; Kenerson HL; Moon RT; Yeung RS
    J Biol Chem; 2003 Feb; 278(8):5947-51. PubMed ID: 12511557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling through beta-catenin and Lef/Tcf.
    Novak A; Dedhar S
    Cell Mol Life Sci; 1999 Oct; 56(5-6):523-37. PubMed ID: 11212302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway.
    Amit S; Hatzubai A; Birman Y; Andersen JS; Ben-Shushan E; Mann M; Ben-Neriah Y; Alkalay I
    Genes Dev; 2002 May; 16(9):1066-76. PubMed ID: 12000790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
    Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Domains of axin involved in protein-protein interactions, Wnt pathway inhibition, and intracellular localization.
    Fagotto F; Jho Eh; Zeng L; Kurth T; Joos T; Kaufmann C; Costantini F
    J Cell Biol; 1999 May; 145(4):741-56. PubMed ID: 10330403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
    Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
    J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiological regulation of [beta]-catenin stability by Tcf3 and CK1epsilon.
    Lee E; Salic A; Kirschner MW
    J Cell Biol; 2001 Sep; 154(5):983-93. PubMed ID: 11524435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
    Huang J; Wu S; Wu CL; Manning BD
    Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuberin phosphorylation regulates its interaction with hamartin. Two proteins involved in tuberous sclerosis.
    Aicher LD; Campbell JS; Yeung RS
    J Biol Chem; 2001 Jun; 276(24):21017-21. PubMed ID: 11290735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
    Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
    J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions.
    Zeng X; Huang H; Tamai K; Zhang X; Harada Y; Yokota C; Almeida K; Wang J; Doble B; Woodgett J; Wynshaw-Boris A; Hsieh JC; He X
    Development; 2008 Jan; 135(2):367-75. PubMed ID: 18077588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control of beta-catenin stability: reconstitution of the cytoplasmic steps of the wnt pathway in Xenopus egg extracts.
    Salic A; Lee E; Mayer L; Kirschner MW
    Mol Cell; 2000 Mar; 5(3):523-32. PubMed ID: 10882137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of Wnt signaling by Axin and Axil.
    Kikuchi A
    Cytokine Growth Factor Rev; 1999; 10(3-4):255-65. PubMed ID: 10647780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex.
    Nellist M; Verhaaf B; Goedbloed MA; Reuser AJ; van den Ouweland AM; Halley DJ
    Hum Mol Genet; 2001 Dec; 10(25):2889-98. PubMed ID: 11741832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TSC1 and TSC2: genes that are mutated in the human genetic disorder tuberous sclerosis.
    Sampson JR
    Biochem Soc Trans; 2003 Jun; 31(Pt 3):592-6. PubMed ID: 12773162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex.
    Liang N; Zhang C; Dill P; Panasyuk G; Pion D; Koka V; Gallazzini M; Olson EN; Lam H; Henske EP; Dong Z; Apte U; Pallet N; Johnson RL; Terzi F; Kwiatkowski DJ; Scoazec JY; Martignoni G; Pende M
    J Exp Med; 2014 Oct; 211(11):2249-63. PubMed ID: 25288394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of TSC2 by 14-3-3 binding.
    Li Y; Inoki K; Yeung R; Guan KL
    J Biol Chem; 2002 Nov; 277(47):44593-6. PubMed ID: 12364343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tuberous sclerosis complex genes in tumor development.
    Mak BC; Yeung RS
    Cancer Invest; 2004; 22(4):588-603. PubMed ID: 15565817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.